ADAR1 Capital Management, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001940272
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 159 positions · Total reported value $188.68M · Top-10 concentration 59.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 47.5% · 33 new · 62 cut · 48 exited
Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2023 13F filing, ADAR1 Capital Management, LLC disclosed 159 equity positions with a combined reported value of $188.68M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.5% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were RPRX ($37.13M), KROS ($27.37M), BBIO ($7.47M). By sector, the heaviest allocations are Health Care 70.5%, Consumer Staples 1.5%.
Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions.
The largest new positions opened in Q4 2023 were RPRX ($37.13M), KROS ($27.37M), BBIO ($7.47M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- RPRX ROYALTY PHARMA PLC · $37.13M
- KROS KEROS THERAPEUTICS INC · $27.37M
- BBIO BRIDGEBIO PHARMA INC · $7.47M
- MACK MERRIMACK PHARMACEUTICALS IN · $7.37M
- MRTX MIRATI THERAPEUTICS INC · $6.34M
- MRK MERCK & CO INC · $5.89M
- ASND ASCENDIS PHARMA A/S · $5.78M
- IMVT IMMUNOVANT INC · $5.65M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-11 | Buy | NextCure, Inc. | 12,333 | $5.10 | SEC filing |
| 2026-11-06 | Buy | NextCure, Inc. | 3,662 | $5.10 | SEC filing |
| 2026-11-05 | Buy | InMed Pharmaceuticals Inc. | 2,640 | $13.10 | SEC filing |
| 2026-11-05 | Buy | NextCure, Inc. | 1,024 | $5.10 | SEC filing |
| 2026-10-27 | Buy | NextCure, Inc. | 3,553 | $5.10 | SEC filing |
| 2026-10-26 | Buy | NextCure, Inc. | 1,672 | $5.03 | SEC filing |
| 2026-10-23 | Buy | InMed Pharmaceuticals Inc. | 4 | $1.32 | SEC filing |
| 2026-10-23 | Buy | NextCure, Inc. | 5,626 | $4.83 | SEC filing |
Fund Profile
ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Firm Snapshot
- Headquarters: AUSTIN, TX, United States
- SEC registration: 801-130082 (status: Approved), registered 2024-04-25
- Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 268 positions · $1.81B reported value (Q2 2026)
- Top 10 holdings = 34.2% of reported value
- Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
- Average position size: $6.74M
Sector Tilt
- Health Care 86.5%
- Financials 2.6%
- Industrials 0.4%
- (classified holdings cover 90% of value)
Quarterly Activity
- Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
- 67 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.32M | $37.13M | 19.68% | New | |
| 2 |
|
688.32K | $27.37M | 14.51% | New | |
| 3 |
|
185.14K | $7.47M | 3.96% | New | |
| 4 |
|
549.42K | $7.37M | 3.90% | New | |
| 5 |
|
108.00K | $6.34M | 3.36% | New | |
| 6 |
|
54.00K | $5.89M | 3.12% | New | |
| 7 |
|
45.88K | $5.78M | 3.06% | New | |
| 8 |
|
134.12K | $5.65M | 3.00% | New | |
| 9 |
|
254.15K | $4.73M | 2.51% | New | |
| 10 |
|
200.86K | $4.61M | 2.44% | New | |
| 11 |
|
637.40K | $4.30M | 2.28% | New | |
| 12 |
|
1.38M | $3.82M | 2.02% | New | |
| 13 |
|
10.00K | $3.17M | 1.68% | New | |
| 14 |
|
478.17K | $2.95M | 1.56% | New | |
| 15 |
|
62.04K | $2.93M | 1.55% | New | |
| 16 |
|
32.00K | $2.92M | 1.55% | New | |
| 17 |
|
56.00K | $2.81M | 1.49% | New | |
| 18 |
|
58.00K | $2.78M | 1.47% | New | |
| 19 |
|
24.50K | $2.70M | 1.43% | New | |
| 20 |
|
50.21K | $2.48M | 1.32% | New | |
| 21 |
|
61.26K | $2.47M | 1.31% | New | |
| 22 |
|
49.00K | $2.46M | 1.30% | New | |
| 23 |
|
50.20K | $2.13M | 1.13% | New | |
| 24 |
|
105.00K | $1.84M | 0.98% | New | |
| 25 |
|
9.50K | $1.82M | 0.96% | New | |
| 26 |
|
8.00K | $1.76M | 0.93% | New | |
| 27 |
|
1.07M | $1.57M | 0.83% | New | |
| 28 |
|
185.89K | $1.57M | 0.83% | New | |
| 29 |
|
191.25K | $1.47M | 0.78% | New | |
| 30 |
|
245.50K | $1.26M | 0.67% | New | |
| 31 |
|
15.00K | $1.23M | 0.65% | New | |
| 32 |
|
111.33K | $1.16M | 0.62% | New | |
| 33 |
|
53.29K | $1.15M | 0.61% | New | |
| 34 |
|
63.62K | $1.05M | 0.56% | New | |
| 35 |
|
132.96K | $1.04M | 0.55% | New | |
| 36 |
|
54.10K | $978.13K | 0.52% | New | |
| 37 |
|
231.30K | $962.22K | 0.51% | New | |
| 38 |
|
275.00K | $888.25K | 0.47% | New | |
| 39 |
|
80.00K | $848.00K | 0.45% | New | |
| 40 |
|
8.06K | $777.42K | 0.41% | New | |
| 41 |
|
75.00K | $777.00K | 0.41% | New | |
| 42 |
|
174.72K | $707.60K | 0.38% | New | |
| 43 |
|
24.00K | $660.00K | 0.35% | New | |
| 44 |
|
6.35K | $656.91K | 0.35% | New | |
| 45 |
|
713.03K | $650.64K | 0.34% | New | |
| 46 |
|
272.16K | $612.36K | 0.33% | New | |
| 47 |
|
20.00K | $546.60K | 0.29% | New | |
| 48 |
|
50.00K | $530.00K | 0.28% | New | |
| 49 |
|
10.00K | $502.90K | 0.27% | New | |
| 50 |
|
17.40K | $500.95K | 0.27% | New | |
FAQ
What did ADAR1 Capital Management, LLC buy in 2023-Q4?
In its 2023-Q4 13F filing, ADAR1 Capital Management, LLC reported 159 equity positions worth $188.68M in aggregate; its largest disclosed positions were RPRX ($37.13M), KROS ($27.37M), BBIO ($7.47M).
How large is ADAR1 Capital Management, LLC's portfolio?
ADAR1 Capital Management, LLC reported $188.68M of long equity holdings across 159 positions as of 2023-Q4. Top-10 holdings account for 59.5% of reported value.
What is ADAR1 Capital Management, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.